B
Bartomeu Massuti
Researcher at Universidad Miguel Hernández de Elche
Publications - 178
Citations - 14535
Bartomeu Massuti is an academic researcher from Universidad Miguel Hernández de Elche. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 39, co-authored 160 publications receiving 12519 citations. Previous affiliations of Bartomeu Massuti include University of Zaragoza & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell,Teresa Moran,Cristina Queralt,Rut Porta,Felipe Cardenal,Carlos Camps,Margarita Majem,Guillermo Lopez-Vivanco,Dolores Isla,Mariano Provencio,A. Insa,Bartomeu Massuti,José Luis González-Larriba,Luis Paz-Ares,Isabel Bover,Rosario García-Campelo,Miguel Angel Moreno,Silvia Catot,Christian Rolfo,Noemi Reguart,Ramon Palmero,Jose Miguel Sanchez,Roman Bastus,Clara Mayo,Jordi Bertran-Alamillo,Miguel Angel Molina,Jose Javier Sanchez,Miquel Taron +27 more
TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.
Journal ArticleDOI
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
Felipe Cardenal,M. Paz López-Cabrerizo,Antonio Antón,Vicente Alberola,Bartomeu Massuti,Alfredo Carrato,Isidoro Barneto,M. Lomas,Margarita García,Pilar Lianes,Joaquín Montalar,C. Vadell,José Luis González-Larriba,Binh Bui Nguyen,Angel Artal,Rafael Rosell +15 more
TL;DR: Compared with etoposide-cisplatin, gemcitabine-c isplatin provides a significantly higher response rate and a delay in disease progression without impairing QOL in patients with advanced NSCLC.
Journal ArticleDOI
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
M. Cobo,Dolores Isla,Bartomeu Massuti,Ana Montes,Jose Miguel Sanchez,Mariano Provencio,Nuria Viñolas,Luis Paz-Ares,Guillermo Lopez-Vivanco,Miguel Angel Muñoz,Enriqueta Felip,Vicente Alberola,Carlos Camps,Manuel Domine,Jose Javier Sanchez,Maria Sanchez-Ronco,K. D. Danenberg,Miquel Taron,David R. Gandara,Rafael Rosell +19 more
TL;DR: Assessment of ERCC1 mRNA expression in patient tumor tissue is feasible in the clinical setting and predicts response to docetaxel and cisplatin, and a multibiomarker profile predictive of patient outcome is refined.
Journal ArticleDOI
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Mariano Provencio,Ernest Nadal,A. Insa,M.-R. García-Campelo,Joaquín Casal-Rubio,Manuel Domine,Margarita Majem,Delvys Rodriguez-Abreu,Alex Martinez-Marti,Javier de Castro Carpeño,Manuel Cobo,Guillermo López Vivanco,Edel del Barco,Reyes Bernabe Caro,Nuria Viñolas,Isidoro Barneto Aranda,Santiago Viteri,E. Pereira,Ana Royuela,M. Casarrubios,Clara Salas Antón,Edwin Roger Parra,Ignacio I. Wistuba,Virginia Calvo,Raquel Laza-Briviesca,Atocha Romero,Bartomeu Massuti,Alberto Cruz-Bermúdez +27 more
TL;DR: The results support the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with resectable stage IIIA NSCLC and could change the perception of locally advanced lung cancer as a potentially lethal disease to one that is curable.